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Members of the ras oncogene family are mutated in a high propor-
tion of human cancers (Kiarkis and Spandidos, 1995), leading to
constitutive Ras activation. The overall incidence of ras mutations
in cancer is of the order of 30% ranging from 80–90% in pancre-
atic cancers, 30–60% in colorectal cancers and 30–60% in lung
cancers. Targeting Ras and the signalling pathways activated by
the mutant oncogene is consequently one of the new approaches
taken in the development of novel cancer therapies (Boral et al,
1998). Identifying direct or surrogate markers for the efficacy of
such treatments could present another challenge. In this context,
magnetic resonance spectroscopy (MRS), if able to detect meta-
bolic changes associated with Ras activation or inhibition, could
provide a useful non-invasive tool. 
1H and 31P MRS can be utilized to detect choline, phosphocholine
(PC) and glycerophosphocholine (GPC) and to monitor tumour
phospholipid metabolism in treated cells and tumours (Podo, 1999
and references therein). At the same time, recent investigations of
Ras signalling have demonstrated that the activities of enzymes
involved in phosphatidylcholine metabolism, as well as the levels of
several choline-containing metabolites are altered following Ras
activation. An increase in cellular choline, phosphocholine as well
as diacylglycerol (DAG) and GPC have been reported in ras trans-
fected NIH 3T3 cells, oocytes, and C3H10T cells (Lacal et al, 1987;
Price et al, 1989; Lacal, 1990; Teegarden et al, 1990; Ratnam and
Kent, 1995). These variations have been explained by changes in
the activities of choline kinase or CTP-PC cytidyltransferase
(Teegarden et al, 1990; Ratnam and Kent, 1995; Weiprecht et al,
1996); activation of a phosphatidylcholine (PdylCh) specific phos-
pholipase C (Lopez-Barahona et al, 1990; Carnero et al, 1994;
Bjorkoy et al, 1995; Podo et al, 1996); phospholipase D (Carnero et
al, 1994) or phospholipase A2 (Lin et al, 1993; Heasley et al, 1997).
Using MRS, an increase in PC levels was detected in Schwann cells,
following transfection with H-ras combined with the SV40 large T
antigen (Bhakoo et al, 1996), whereas the comparison of a series of
human breast cancer cell lines has shown a correlation between an
increasingly transformed phenotype and higher PC/GPC levels
(Aboagye and Bhujwalla, 1999). 
Using NIH 3T3 cells, a well established model for investigating
ras transformation, the purpose of this work was to determine
whether MRS can be used to detect the alterations in choline
metabolism associated with ras transformation. Furthermore, we
aimed to assess the usefulness of MRS in non-invasively moni-
toring response to novel therapies targeted at the Ras signalling
pathways. By comparing NIH 3T3 cells with their mutant H-ras
transfected counterparts we determined that MRS can detect
a significant increase in PC levels following Ras activation.
Subsequent to treatment with 3 different inhibitors of Ras
signalling, this increase in PC was partially reversed in the ras
transfected cell line. We speculate that PC or the PC/NTP ratio
could be used as surrogate MRS markers for ras transformation
and response to Ras targeting therapies. 
MATERIALS AND METHODS 
NIH 3T3 mouse fibroblasts and D12Hras1C (D12H) cells trans-
fected with the H-ras gene mutated at codon 12 were kindly
provided by C Marshall and L Kelland. Cells were maintained
in DMEM (Gibco UK) supplemented with 5% horse serum,
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CO2 atmosphere. 
To characterize cell proliferation, growth curves were determined
by counting trypsinized cells every 24 h over 8 days using a Coulter
Act 8 counter. Cell cycle analysis was performed on cells fixed in
70% ethanol, treated with 100 mgm l -1RNase A in PBS and stained
with 4 mgm l -1 propidium iodide, using an Elite ESP Beckman
coulter cell sorter at 488 nm. Data were analysed using the WinMdi
and Cylchred software (University of Wales College of Medicine).
To determine total protein content, cells were lysed and pro-
tein content determined using a DC protein assay kit (Biorad)
and measuring absorbance at 750 nm using BSA as standard.
Alternatively, the protein precipitate obtained from cells ex-
tracted for MRS investigations was dissolved by heating to 60˚C
in 1M NaOH and protein content determined as above. To inhibit
Ras signalling cells were treated either with 20 mM simvastatin
(courtesy of Merck Sharp & Dohme UK; stock solution prepared
in DMSO and diluted 1:5000) for 24 h or with 1.3 mM 17-AAG
(courtesy of NCI; stock solution in DMSO and diluted 1:5000)
for 30 h, or with 1 mM R115777 (courtesy of Janssen; stock solu-
tion in water diluted 1:1000) for 72 h. In every case appropriate
carrier treated (DMSO or water) controls were used. To assess
levels of protein expression ca. 2 ´ 106 trypsinized cells were
lysed in 50 ml sample buffer (50% buffer II (0.25 M Tris base,
6.9 mM sodium dodecylsulphate (SDS) at pH 6.8), 4% SDS,
2% dithiothreitol, (10% glycerol, 5% 0.1 M phenylmethyl-
sulphonylfluoride and water), and heated to 90˚C for 5 min.
Samples were loaded onto a 10% (for ERK, Raf, GAPDH) or
13% (for Ras) polyacrylamide gel, separated by electrophoresis
and transferred onto an immobilon-P membrane for 1 h at 80 mA
using transfer buffer (15% methanol, 0.3% Tris, 1.44% glycine
and water). Immunoblots were blocked overnight in 5% non-fat
milk in wash buffer (0.01 M Tris, 0.1 M NaCl at pH 7.5) and
probed for 1 h with one of the following: anti-Ras mouse mono-
clonal antibody (Transduction Laboratories USA); anti-Raf-1
rabbit polyclonal antibody (Santa Cruz Biotechnology USA);
anti-ERK rabbit polyclonal antibody (New England Biolabs
USA); anti-P-ERK mouse monoclonal antibody (Sigma UK);
anti-GAPDH mouse monoclonal antibody (Chemicon Inter-
national USA). Specific antigen–antibody interactions were
detected with horseradish peroxidase-linked secondary antibody
using enhanced chemiluminescence Western blotting detection
reagents (Amersham Pharmacia Biotech UK). 
To obtain an MR spectrum 2–4 ´ 107 cells in logarithmic phase
were extracted as previously described (Tyagi et al, 1996; Ronen
et al, 1999). Briefly, cells were rinsed with ice cold saline, then
covered with ice-cold methanol, scraped off the culture flask
surface, collected and vortexed. An equal volume of chloroform
was then added followed by an equal volume of de-ionized water.
Following phase separation and solvent removal samples were
stored at -80˚C. Prior to acquisition of the MRS spectra the water
soluble metabolites were resuspended in D2O with 10 mM EDTA
at pH 8.2 and the lipids were resuspended in CDCl3 supplemented
with methanolic EDTA. MRS spectra were acquired at room
temperature on a 400 MHz Bruker spectrometer at 161 MHz using
a 90˚ flip angle, a 7 s relaxation delay and broad band proton
decoupling during acquisition. Metabolite contents were deter-
mined by integration, normalized relative to an internal reference
(methylenediphosphonic acid in the case of water soluble meta-
bolites and trimethylphosphate in the case of lipids) and corrected
for saturation and the number of cells extracted. 
Results represent an average of at least 3 repetitions and are
expressed as mean ± SD. Statistical significance was determined
using one way ANOVA (Arcus Quickstat – Longman Software
Publishing) and differences were assumed to be significant when
P <0.05. 
RESULTS 
Western blots confirmed that Ras levels were higher in the
ras transfected D12H cell line (Figure 1A). To determine the level
of signalling through the Ras-Raf-MEK-ERK pathway the
levels of both total ERK, and the phosphorylated form of ERK
were determined by Western blotting. As illustrated in Figure 1B
the levels of phosphorylated ERK were higher in the ras trans-
fected D12H cells whereas total ERK levels indicate that the
overall protein levels were not substantially altered following
transfection. Western blotting for GAPDH was used to confirm
equal loading of samples. 
Cell growth was characterized by determining the proliferation
rate of the cells as well as the cell cycle distribution. We deter-
mined that the doubling time was 28 ± 4 hours for NIH 3T3 cells
and 32 ± 4 hours for D12H cells (n = 8, P = 0.07). The cell cycle
distribution of exponentially growing NIH 3T3 cells was 64 ± 8%
in G1, 7 ± 3% in G2 and 29 ± 6% in S phase. In the D12H cells the
cell cycle distribution was altered: 40 ± 4% of cells were in G1,
20 ± 5% of cells were in G2 and 40 ± 5% of cells were in S phase
during the mid-logarithmic phase (P < 0.03 for G1). 
Protein content was determined from cells extracted for
this purpose and confirmed from protein precipitates obtained
following cell extractions for MRS. The protein content of NIH
3T3 cells was 249 ± 28 pg cell-1 and increased significantly to
391 ± 61 pg cell-1 in D12H cells (P < 0.001). 
Figure 2 illustrates the 31P MRS spectra obtained from extracts
of NIH 3T3 and D12H cells. To rule out the effects of cell cycle
arrest due to confluence, care was taken to perform all investiga-
tions when cells were in mid-logarithmic phase. The average
PC content of NIH 3T3 cells was 3 ± 2 fmol cell-1 (n = 5) signifi-
cantly increasing to 13 ± 4 fmol cell-1 (n = 5) in the D12H cells
(P < 0.001). Cellular NTP content also increased upon ras trans-
fection from 13 ± 3 fmol cell-1 to 20 ± 7 fmol cell-1 (P < 0.04). The
PC/NTP ratio was 0.3 ± 0.1 in NIH 3T3 cells and increased signi-
ficantly to 0.7 ± 0.3 in the D12H cells (P < 0.001). The GPC signal
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Figure 1 Western blot analysis determining expression of (A) Ras and (B)
phosphorylated ERK and total ERK proteins in NIH 3T3 (NIH) cells and D12H
ras-transfected cells. GAPDH was used to confirm equal sample loading.
Lanes marked 1:4 were loaded with sample diluted 1:4 relative to the
neighbouring lane was not always detectable by MRS and no statistically significant
differences between the two cell lines could be observed. 
To determine whether the levels of phosphatidylcholine were
also altered following ras transformation, spectra were recorded
from the chloroform phase of the cell extracts. No statistically
significant difference between NIH 3T3 and D12H cells was
observed. Phosphatidylcholine represented 48 ± 13% of total
phospholipid content in NIH 3T3 cells and 49 ± 3% in D12H cells.
This indicated that any change in the phospholipid content is
below detection level by MRS, and cellular phosphatidylcholine
level was not substantially affected by the increase in its precursor
phosphocholine. 
To further ascertain that our observations were correlated with
the activation of Ras, and to determine whether MRS could be
used to assess response to Ras targeting therapies, we treated both
cell lines with 3 different inhibitors of the Ras pathway – R115777,
simvastatin and 17-AAG. R115777 is an inhibitor of the farnesyl-
transferase enzyme which catalyses binding of a farnesyl moiety to
the Ras protein (the farnesyl is required for localization of Ras to
the cell membrane) (Zujewski et al, 2000). Simvastatin is an
HMG-CoA reductase inhibitor which inhibits synthesis of the
farnesyl moiety (Leonard et al, 1990). 17-AAG is an HSP90-
binding protein and causes depletion of several proteins including
Raf, downstream of Ras in signalling to ERK (Schulte and Necker,
1998). Figure 3 illustrates the results of Western blotting for phos-
phorylated ERK. As indicated by the drop in P-ERK levels, all 3
inhibitors caused an inhibition of signalling through the Ras-
Raf-MEK-ERK pathway. This inhibition was more marked in the
case of D12H cells. Following treatment with 17-AAG a substan-
tial drop in total Raf levels was also observed in both cell lines but
total ERK was not altered following any of the treatments (data not
shown). 
Treatment with the Ras inhibitors also inhibited cell prolifera-
tion as illustrated in Figures 4A and 4E (NIH 3T3 and D12H
cells respectively). In the case of NIH 3T3 cells, the number of
cells per flask dropped to 72 ± 15% following R115777 treatment
(P < 0.03), 61 ± 15% following simvastatin treatment (P < 0.03),
and 24 ± 16% following 17-AAG treatment (P < 0.01) relative to
control. In the case of D12H cells the number of cells per flask
dropped to 62 ± 15% following simvastatin treatment (P < 0.05),
and to 32 ± 4% following 17-AAG treatment (P < 0.005) relative
to control. Following treatment with R115777, a drop in cell
number per flask was observed but was not statistically significant
(down to 88 ± 12%, P = 0.2). 
Treatment affected the cell cycle distribution in the same
manner in both cell lines. R115777 and 17-AAG did not signific-
antly alter the distribution in either cell line. In contrast simvastatin
caused an arrest in the G1 phase of the cycle in both lines. In NIH
3T3 cells, the cell cycle distribution following treatment was
83 ± 4% in G1, 4 ± 1% in G2 and 13 ± 4% in S, and in the D12H
cells the distribution was 77 ± 4% in G1, 7 ± 2% in G2 and 16 ± 2%
in S phase. Total protein content was not significantly affected by
treatment in either cell line. 
The MRS spectra of treated and control cell extracts indicated
that for NIH 3T3 cells, the inhibition of Ras signalling and cell
growth was not accompanied by any significant changes in the
metabolites present in the 31P MRS spectrum (Figure 4B–D).
Within experimental error PC and NTP levels remained constant
following all 3 treatments. In contrast, in the case of D12H ras-
transfected cells, the inhibition in cell growth and Ras signalling
were accompanied by a significant drop in the levels of PC (Figure
4F). PC content dropped from 17 ± 5 in DMSO-treated controls to
11 ± 1 fmol cell-1 following treatment with simvastatin (P < 0.02)
and to 11 ± 1 fmol cell-1 following treatment with 17-AAG (P <
0.01). The increase observed in PC levels in the DMSO treated
controls versus untreated control (13 ± 3 versus 17 ± 5) was not
statistically significant (P = 0.3) The levels of NTP in the treated
D12H cells remained unchanged within experimental error (Figure
4G) thus PC/NTP (Figure 4H) dropped significantly from 0.8 ± 0.1
in DMSO treated controls to 0.4 ± 0.1 following treatment with
17-AAG (P < 0.04) and to 0.6 ± 0.1 following simvastatin treat-
ment (P < 0.03). Treatment with R115777 was also accompanied
by a drop in PC from 13 ± 4 to 8 ± 6 fmol cell-1, as well as a drop
in PC/NTP from 0.7 ± 0.3 to 0.4 ± 0.1 but these did not reach
statistical significance (P = 0.06). 
DISCUSSION 
To assess the effect of Ras activation and its inhibition using MRS
we chose to concentrate on the extensively studied NIH 3T3
mouse fibroblast line and a mutant ras-transfected counterpart. By
Western blotting for Ras and phosphorylated ERK, we confirmed
that Ras signalling was increased in the transfected D12H cells
relative to the parent NIH 3T3 line. The MRS investigations of
cell extracts showed a significant difference in metabolite content
following ras transfection. NTP levels were higher in the ras trans-
fected cells, but the most significant difference was in phospho-
choline content which was more than 4 fold higher per cell
in D12H. If metabolite content was normalized to mg protein,
NTP content was unaltered by Ras (both cell lines contain
Magnetic resonance detection of Ras 693
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Figure 2 31P MRS spectra of the water soluble metabolites obtained from
NIH 3T3 and D12H cell extracts. The spectrum was plotted with a line
broadening of 0.2Hz. PC: phosphocholine: Pi: inorganic phosphate; NTP:
nucleoside triphosphates
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Figure 3 Western blot analysis determining expression of phosphorylated
ERK in NIH 3T3 (NIH) and D12H cells treated with R115777, simvastatin
(sim), and 17-AAG compared to matched controls 5 nmoles mg-1 protein). However, PC levels showed an almost
3-fold increase from 12 nmol mg-1 protein in the NIH 3T3 cell to
33 nmol mg-1 protein in the D12H line. The average PC/NTP ratio,
a parameter independent of cell number or protein content, also
increased significantly by more than 2-fold indicating that this
ratio could serve as an MRS marker of Ras activation. 
Previous MRS work has shown that PC levels can be affected
by the proliferation state of the cells, with a drop in PC content
observed in quiescent cells (Ronen et al, 1992; Podo, 1999). To
avoid this problem care was taken to compare cells which were in
the logarithmic phase of their growth, excluding cell populations
which could be arrested due to confluence or nutrient deprivation. 
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the relative change in average values). * Signifies statistical significance (P < 0.05)The increase in PC levels in transformed cells and tumours
has been postulated as resulting from an increase in phospho-
lipid synthesis to produce membranes required during cell divi-
sion (Negendank, 1992; Podo, 1999). Our results show that the -
ras-transfected cell line which has a higher PC content, has
a doubling time comparable within experimental error to the
doubling time of the control cells. Thus, in this model, PC levels
were not associated with altered doubling time. This observation is
in agreement with some previously published data (Ting et al,
1996; Aboagye and Bhujwalla, 1999). 
Previous MRS work has also shown a correlation between S
phase fraction and PC levels (Smith et al, 1991). We observed a
shortening of the G1 phase of the cell cycle in the ras-transfected
D12H cells. This probably results from the control by Ras
of cyclin D (Liu et al, 1995; Gille and Downward, 1999). We
cannot rule out that in our cells this drop in G1 contributes to
the observed increase in PC. However this is probably not the
only explanation for our results: even if PC levels were unde-
tectable during the G1 phase with PC originating exclusively
from cells in G2 + S, the observed increase in the G2 + S fraction
from 36% to 60% following ras transfection would not be suffi-
cient to explain the 4-fold increase in PC content per cell
observed in the D12H cells. 
To further confirm that the increase in PC levels was due to Ras
activation and to assess whether MRS could be used to detect the
effects of Ras targeting therapies we treated both cell lines with 3
inhibitors of the Ras signalling pathway. We chose 2 inhibitors
which would affect all pathways downstream of Ras (simvastatin
and R115777) and a third inhibitor which should primarily affect
the Ras-Raf-MEK-ERK pathway by depleting Raf (17-AAG).
Whereas the spectrum of NIH 3T3 cells was not affected by treat-
ment, D12H cells showed a drop in PC levels after treatment. The
3 inhibitors affected cell viability and cell cycle distribution of the
control and transfected cell lines in the same way, ruling out differ-
ential response to treatment as an explanation of our results. Our
findings lead to the conclusion that the MR detectable drop in PC
is associated with inhibition in Ras signalling and cell proliferation
only in the cells which over-expressed ras. This indicates that the
initial increase in PC and PC/NTP and its subsequent partial drop
following treatment probably reflect the presence of the mutant
activated Ras protein. 
Our results require further confirmation in other models,
including human cell lines expressing mutant Ras. None-
theless, this study indicates that MRS could be useful in non-
invasively monitoring Ras activation as well as response to 
novel, Ras targeting therapies, with phosphocholine and 
PC/NTP levels serving as surrogate markers for mutant Ras activity. 
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